

# 4<sup>th</sup> EFSPI Workshop on Regulatory Statistics

**23/24<sup>th</sup> September 2019 Basel (CH)**

After three very successful workshops on regulatory statistics in the past three years, EFSPI is pleased to announce the 4<sup>th</sup> regulatory statistics workshop taking place in Basel on 23<sup>rd</sup> and 24<sup>th</sup> September 2019.

The workshop will be dedicated to the discussion of opportunities and challenges of statistical topics between regulators, academics, and industry with dedicated time for interaction and discussion.

Members of the Scientific Committee are: Egbert Biesheuvel, Andreas Brandt, Hans Ulrich Burger, Christoph Gerlinger, Randi Gron, Benjamin Hofner, Armin Koch, Flavia Lombardo, Frank Petavy, Khadija Rantell, Kaspar Rufibach, Anja Schiel, Emmanuel Zuber.

## **Monday 23<sup>rd</sup> September**

- 13:30 Welcome**
- 13:40 Session 1: Real-world data – beyond randomized clinical trials**
- 15:10 Coffee break**
- 15:40 Session 2: Real-world data – applications**
- 17:10 Panel discussion with all speakers**
- 18:00 Reception**

## **Tuesday 24<sup>th</sup> September**

- 09:00 Session 3: Analysis of safety in clinical trials – or how to bring a statistician out of his comfort zone**
- 10:30 Coffee break**
- 11:00 Session 4: Estimands – are we pushing any boundaries thanks to the ICH E9 addendum?**
- 12:30 Lunch break**
- 13:30 Session 5: Modern approaches for rare disease**
- 15:00 Coffee break**
- 15:30 Session 6: Contributed short topics – discussions**
- 16:45 Official closure of the meeting**



## **Venue**

Oekolampad Church  
Allschwilerplatz 22  
CH – 4055 Basel  
Switzerland

## **Registration Costs**

Fee includes lunch & refreshments

### **Early bird before or on 15<sup>th</sup> of August**

Industry	€250
Academic	€175

### **After 15<sup>th</sup> of August**

Industry	€300
Academic	€225

## **Hotel Rooms**

Bildungszentrum 21

<http://www.bildungszentrum-21.ch>

(mention EFSPI workshop)

**To Register Please Go To**  
[www.efspi.org](http://www.efspi.org)

### **Or contact:**

EFSPI Secretariat  
Tel: +44 (0)1625 664549  
[efspi@kingstonsmith.co.uk](mailto:efspi@kingstonsmith.co.uk)

**For information on the scientific content, contact the Scientific Committee**

**Proposals for short topics for Session 6, please contact either Armin Koch ([koch.armin@mh-hannover.de](mailto:koch.armin@mh-hannover.de)) or Hans Ulrich Burger ([hans\\_ulrich.burger@roche.com](mailto:hans_ulrich.burger@roche.com)) by August 31<sup>st</sup>**



## 4<sup>th</sup> EFSPI Workshop on Regulatory Statistics

	<u>23<sup>rd</sup> September</u>
13:30-13:40	<b>Welcome</b>
13:40-15:10 90min	<b>Session 1: Real-world data – beyond randomized clinical trials</b> <b>Chairs:</b> Benjamin Hofner & Christoph Gerlinger
	<p><b>Kit Roes (Utrecht Medical Center)</b> RWD, RWE, big data, external control, digital biomarker – what do they all mean? (25min)</p> <p><b>Dominik Heinzmann (Roche, absent) and Simon Wandel (Novartis)</b> BBS spring seminar external controls: summary &amp; what happened since then? (25min)</p> <p><b>Fabian Model (Roche)</b> Development of a digital endpoint in Multiple Sclerosis - challenges and opportunities (20min)</p> <p><b>Hendrik Schmidt (Boehringer-Ingelheim)</b> A look on Best Practices in Pragmatic Trials (20min)</p>
15:10-15:40	<b>Coffee break</b>
15:40-17:25 105min	<b>Session 2: Real-world data – applications</b> <b>Chairs:</b> Frank Petavy & Hans Ulrich Burger
	<p><b>Kate Taylor (Amgen)</b> Single-arm study plus a historical comparator equals two historic regulatory approvals – my experiences with the Blincyto MRD filings (20min)</p> <p><b>Stanislas Hubeaux (Roche)</b> Development of a smartphone based monitoring tool for people with Multiple Sclerosis - challenges and opportunities (20min)</p> <p><b>Christoph Gerlinger (Bayer)</b> Using RWD to extrapolate evidence from RCTs (20min)</p> <p><b>Benjam Hofner (PEI) and Khadija Rantell (MHRA)</b> RWD aspects in a gene-therapy approval (20min)</p> <p><b>Stephen Evans (London School of Hygiene and Tropical Medicine)</b> How far can we trust the Real World? (25min)</p>
17:25-18:00 35min	<b>Panel discussion with the chairs and all speakers</b>
17:45-19:00	<b>Reception – German and French wine tasting!</b>

<b>24<sup>th</sup> September</b>	
09:00-10:30 90min	<p><b>Session 3: Analysis of safety in clinical trials – or how to bring a statistician out of his comfort zone</b>  <b>Chairs:</b> Khadija Rantell &amp; Marcel Wolbers</p> <p><b>Tim Friede (University of Goettingen, on behalf of SAVVY working group)</b>  Comparison of statistical methods to analyse safety data (15min)</p> <p><b>Gian Thanei (Roche)</b>  Pooling and harmonizing of safety data for a robust statistical analysis (15min)</p> <p><b>Steffen Falgreen Larsen (Novo Nordisk)</b>  A shiny app to explore hypoglycemic episodes and adverse events for a pool of trials (15min)</p> <p><b>John Johnston (MHRA)</b>  Matching up (15min)</p> <p><b>Hans Ulrich Burger (Roche)</b>  How statisticians deal with the difference between efficacy and safety reporting (10min)</p> <p><b>Panel discussion with the chairs and all speakers (20min)</b></p>
10:30-11:00 30min	<b>Coffee break</b>
11:00-12:30 90min	<p><b>Session 4: Estimands – are we pushing any boundaries thanks to the ICH E9 addendum?</b>  <b>Chairs:</b> Andreas Brandt &amp; Kaspar Rufibach</p> <p><b>Khadija Rantell &amp; Ines Reis (MHRA)</b>  How the estimand framework becomes standard practice in applications, and where we still need to learn (20min)</p> <p><b>Georg Kralidis (Gruenthal) and Marcel Wolbers (Roche)</b>  Treatment policy and hypothetical strategies for intercurrent events in chronic pain and Parkinson’s disease (20min)</p> <p><b>Evgeny Degtyarev (Novartis)</b>  Estimand framework: opportunity to rethink some old (and new) problems in Oncology (15min)</p> <p><b>Lorenzo Guizzaro (EMA)</b>  Regulatory experience with the estimand framework (15min)</p> <p><b>Panel discussion with the chairs and all speakers (20min)</b></p>
12:30-13:30	<b>Lunch break</b>



13:30-15:00 90min	<b>Session 5: Modern approaches for rare diseases</b> <b>Chairs:</b> Armin Koch & Egbert Biesheuvel
	<b>Lukas Aguirre Davila (Hannover Medical School)</b> Observational vs. randomized analyses of digoxin-mortality in the DIG trial (20min)  <b>Charlotte Gaasterland (Knowledge Institute of the Federation of Medical Specialists)</b> Goal Attainment Scaling: Validation & use for rare disease (20min)  <b>Hilke Zander (PEI)</b> A regulator's view on rare cancer drug development: Histology independent indications (20min)  <b>Panel discussion with the chairs and all speakers &amp; Kit Roes (30min)</b>
15:00-15:30 30min	<b>Coffee break</b>
15:30-16:45 75min	<b>Session 6: Contributed short topics – discussions</b> <b>Chairs:</b> Armin Koch & Hans Ulrich Burger
	Up to 6 topics from practice will briefly be presented (5 min) followed by a 10-15 min discussion of the panel and with audience  Proposals of topics can be addressed until August 31 to either Armin Koch (koch.armin@mh-hannover.de) or Hans Ulrich Burger (hans_ulrich.burger@roche.com)
16:45	<b>Official closure of the meeting</b>

